Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: Is it safe?

Clinical Cardiology

Volumn 33, Issue 10, 2010, Pages 604-608

  Chua, Doson ^a   Lo, Anita ^b   Lo, Chris ^c  

^a ST PAUL S HOSPITAL   (Canada)

^b Ridge Meadows Hospital and Health Care Centre   (Canada)

^c Langley Memorial Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; POTASSIUM; SPIRONOLACTONE;

ARTICLE; CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EMBASE; HEART FAILURE; HEMODIALYSIS; HUMAN; HYPERKALEMIA; INCIDENCE; KIDNEY FAILURE; MEDLINE; META ANALYSIS; POTASSIUM BLOOD LEVEL; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

DIURETICS; HEART FAILURE; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; SPIRONOLACTONE;

EID: 78349303033     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20838     Document Type: Article

References (38)

1. Levin A., Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial. 2003; 16: 101-105. (Pubitemid 37361072)
2. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Part 7-Stratification of risk for progression of kidney disease and development of cardiovascular disease. Am J Kidney Dis. 2002; 39: S170-S212.
3. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Part 4-Definition and classification of stages of chronic kidney disease. Am J Kidney Dis. 2002; 39: S46-S75.
4. Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin and cardiovascular risk. Lancet. 2007; 369: 1208-1219.
5. McMurray JJ, Pfeffer MA., Heart failure. Lancet. 2005; 365: 1877-1889.
6. Yan AT, Yan RT, Liu PP., Narrative review: pharmacotherapy for chronic heart failure: evidence from recent clinical trials. Ann Intern Med. 2005; 142: 132-145.
7. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003; 362: 772-776. (Pubitemid 37093917)
8. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003; 362: 767-771. (Pubitemid 37093916)
9. Cohn JN, Tognoni G., A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345: 1667-1675.
10. Epstein M., Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med. 2001; 94: 378-383.
11. Brewster, EC, Setaro JF, Perazella MA., The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci. 2003; 326: 15-24.
12. Plow EF, D'Souza SE., A role for intercellular adhesion molecule-1 in restenosis. Circulation. 1997; 95: 1355-1356.
13. Brilla CG, Matsubara LS, Weber KT., Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993; 25: 563-575.
14. Rocha R, Funder JW., The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci. 2002; 970: 89-100.
15. Wang W., Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension. 1994; 24: 571-575.
16. Pitt B, Zannad F, Remme WJ, et al. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341: 709-717.
17. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med. 2003;348:2271]. N Engl J Med. 2003; 348: 1309-1321.
18. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009; 119: e391-e479.
19. Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society Consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol. 2006; 22: 23-25.
20. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004; 351: 543-551.
21. Ritz E, Ditkow R, Adamzcak M, et al. Congestive heart failure due to systolic dysfunction: the Cinderella of cardiovascular management in dialysis patients. Semin Dial. 2002; 3: 135-140.
22. Silverberg D, Wexler D, Blum B, et al. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens. 2004; 2: 163-170.
23. Epstein M., Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transplant. 2003; 18: 1984-1992.
24. Ahmed J, Weisberg LS., Hyperkalemia in dialysis patients. Semin Dial. 2001; 14: 348-356.
25. Ramadan FH, Masoodi N, El-Solh AA., Clinical factors associated with hyperkalemia in patients with congestive heart failure. J Clin Pharm Ther. 2005; 30: 233-239.
26. Hausmann MJ, Liel-Cohen N., Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function. Nephrol Dial Transplant. 2002; 17: 2035-2036.
27. Azar R, Hogede L, Carru V., Aldactone therapy in a peritoneal dialysis patient. Nephrol Dial Transplant. 2003; 18: 1232-1233.
28. Hussain S, Dreyfus DE, Marcus RJ, et al. Is spironolactone safe for dialysis patients? Nephrol Dial Transplant. 2003; 18: 2364-2368.
29. Saudan P, Mach F, Perneger T, et al. Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant. 2003; 18: 2359-2363.
30. Michea L, Vukusich A, Gonzalez M, et al. Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients. Kidney Int. 2004; 66: 1647-1653.
31. Gross E, Rothstein M, Dombek S, et al. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis. 2005; 46: 94-101.
32. Taheri S, Mortazavi M, Shahidi S, et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl. 2009; 20: 392-397.
33. Matsumoto Y, Kageyama S, Yakushigawa T, et al. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients. Cardiology. 2009; 114: 32-38.
34. Locatelli F, Carcelli D, Conte F, et al. Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol Dial Transplant. 2000; 15 (suppl 5): S69-S80.
35. Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009; 169: 1156-1162.
36. Salem MM, Rosa RM, Batlle DC., Extrarenal potassium tolerance in chronic renal failure: important implications for the treatment of acute hyperkalemia. Am J Kidney Dis. 1991; 18: 421-440.
37. Aslam S, Friedman EA, Ifudu O., Electrocardiography is unreliable in detecting potentially lethal hyperkalemia in haemodialysis patients. Nephrol Dial Transplant. 2002; 17: 1639-1642.
38. Andrew ME, Jones DW, Wofford MR, et al. Ethnicity and unprovoked hypokalemia in the atherosclerosis risk in communities study. Am J Hypertens. 2002; 15: 594-599.